Chart strategist Katie Stockton breaks down the technical backdrop in CVS.
Get this delivered to your inbox, and more info about our products and services.
With CVS re-establishing forward guidance and offering a deeply discounted valuation, the balance of risk favors upside.
CNBC's Jim Cramer said he's optimistic about CVS and explained to investors why he the healthcare company's stock is worth buying
CVS CEO David Joyner pointed to strength in its retail pharmacy and improvement in its insurance unit, Aetna, which is grappling…
UBS analyst Kevin Caliendo's revised price target implies 15% upside ahead for shares of the health care benefit and pharmacy…
The third-quarter results mark David Joyner's first full year as CEO of CVS, which had struggled to drive higher profits and…
The results signal steady progress in the health-care giant's aggressive turnaround plan under CEO David Joyner, who stepped into…
